Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer

Key Points

• Metastasis rates are significantly linked to ARHGDIB delactylation, promoting aggressive cancer behavior.
• Delactylation of the tumor suppressor correlates with increased chemoresistance in bladder cancer cells.
• This analysis utilizes cellular assays and molecular characterization methods to demonstrate critical pathways.
• These findings highlight potential interventions targeting delactylation in bladder cancer to improve treatment outcomes.